What insulin dosing regimen and preferred basal and bolus insulin agents should be used for adults with type 1 diabetes mellitus, considering comorbid chronic conditions such as cardiovascular disease, chronic kidney disease, chronic liver disease, obesity, pregnancy, and elderly patients?

Insulin Dosing and Agent Selection for Type 1 Diabetes with Comorbidities

Adults with type 1 diabetes should use a basal-bolus insulin regimen with long-acting basal analogues (glargine U-100/U-300, detemir, or degludec) and rapid-acting prandial analogues (aspart, lispro, or glulisine), with specific modifications based on comorbid conditions, particularly in elderly patients where simplified regimens may be necessary.

Standard Insulin Regimen for Type 1 Diabetes

Basal Insulin Selection

• Preferred agents: Long-acting basal analogues including insulin glargine U-100, glargine U-300, detemir, or degludec 1
• These second-generation basal analogues provide reduced peak profiles, extended duration of action, and lower intraindividual variability compared to NPH insulin 1, 2
• Clinical advantages: Reduced injection burden, better efficacy, lower risk of hypoglycemic episodes (especially nocturnal), and reduced weight gain 1
• Insulin glargine U-300 and degludec specifically reduce hypoglycemic events due to more stable action profiles 2

Prandial Insulin Selection

• Preferred agents: Rapid-acting analogues (aspart, lispro, or glulisine) over regular human insulin 1
• Newer options: Faster-acting insulin aspart and ultra-rapid-acting lispro provide superior postprandial glucose control without increased hypoglycemia 2
• These second-generation rapid-acting analogues allow injection closer to or even after meals without compromising postprandial control 2

Dosing Strategy

• Most adults with type 1 diabetes require multiple daily injections of basal-bolus insulin 1
• Prandial insulin should be dosed based on carbohydrate counting, premeal blood glucose, and anticipated physical activity 1
• A bolus/basal ratio <1.5 is associated with better glycemic control; ratios ≥1.5 correlate with higher HbA1c levels 3

Modifications for Specific Comorbidities

Elderly Patients (Most Critical Population)

For healthier older adults:

• Continue standard basal-bolus regimens with frequent glucose monitoring, preferably continuous glucose monitoring 4
• Target fasting glucose: 90-150 mg/dL (5.0-8.3 mmol/L) 5
• Use the same preferred basal and rapid-acting analogues as younger adults 4

For frail elderly or those with poor health status:

• Simplify to basal-only insulin: Use 70% of total daily dose as morning basal insulin only 5
• Preferred basal agents: Glargine U-100/U-300, detemir, degludec, or NPH 5
• Change timing from bedtime to morning administration 5
• Titrate based on fasting glucose over 1 week: increase by 2 units if >50% of values exceed goal; decrease by 2 units if >2 values/week are <80 mg/dL 5

For elderly on premixed insulin:

• Convert to simplified basal-only regimen using 70% of total dose 5
• If prandial insulin >10 units/dose, decrease by 50% and add non-insulin agents (metformin, SGLT2 inhibitors, DPP-4 inhibitors, or GLP-1 RAs) 5
• Titrate prandial insulin down as non-insulin agents are increased, aiming to discontinue prandial insulin 5

Cardiovascular Disease

• GLP-1 receptor agonists with proven cardiovascular benefit should be considered in combination with insulin therapy 6
• For patients on GLP-1 RA and basal insulin, consider fixed-ratio combination products (IDegLira or iGlarLixi) 6
• Standard basal-bolus insulin regimens remain appropriate with the same preferred agents 1

Chronic Kidney Disease

• Basal analogues with stable profiles (glargine U-300, degludec) are preferred to minimize hypoglycemia risk 2
• When simplifying regimens in elderly patients with CKD, use the algorithm for basal-only insulin with careful monitoring 5
• Consider adding SGLT2 inhibitors or GLP-1 RAs for kidney protection when appropriate 5

Obesity

• GLP-1 receptor agonists should be strongly considered in combination with insulin to reduce weight gain 6
• Metformin combined with insulin decreases weight gain, lowers insulin dose requirements, and reduces hypoglycemia 7
• Use standard basal-bolus regimens with preferred analogues 1

Pregnancy

• Rapid-acting analogues (aspart, lispro, glulisine) are safe and effective 1
• Basal analogues are appropriate, though specific pregnancy data varies by agent 1
• More intensive monitoring and tighter glycemic targets are required (not detailed in provided evidence)

Chronic Liver Disease

• Use basal analogues with stable profiles to minimize hypoglycemia risk 2
• Simplify regimens if cognitive impairment is present, following elderly simplification algorithms 5
• Standard basal-bolus approach remains appropriate with careful monitoring 1

Critical Practical Considerations

Hypoglycemia Management

• If hypoglycemia occurs without clear cause, lower the corresponding insulin dose by 10-20% 6
• For elderly patients: if >2 premeal values/week are <90 mg/dL, decrease medication dose 5
• Basal analogues significantly reduce nocturnal hypoglycemia compared to NPH 1, 2

Injection Technique

• Use 4-mm pen needles or 6-mm syringe needles as first-line to avoid intramuscular injection 7
• Rotate injection sites properly to prevent lipohypertrophy, which distorts insulin absorption 7
• Avoid injecting into lipohypertrophic areas 7

Monitoring Requirements

• Frequent blood glucose monitoring is essential for all insulin regimens 1
• Continuous glucose monitoring improves glycemic control regardless of treatment regimen 1
• Fasting plasma glucose guides basal insulin titration; both fasting and postprandial values guide prandial insulin 7

Common Pitfalls

• Avoid therapeutic inertia: Do not delay treatment intensification or modification when goals are not met 6
• Do not abruptly discontinue oral medications when starting insulin due to rebound hyperglycemia risk 7
• Avoid rapid-acting or short-acting insulin at bedtime 5
• Do not use NPH in evening if patient frequently forgets doses; switch to morning long-acting basal analogue 6